Literature DB >> 25922698

Individualizing adjuvant therapy for early stage non-small cell lung cancer: we see the destination, but we don't yet know the route.

Howard West1.   

Abstract

Entities:  

Year:  2015        PMID： 25922698      PMCID： PMC4387408          DOI： 10.3978/j.issn.2072-1439.2015.01.08

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  8 in total

1.  A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.

Authors:  Johannes R Kratz; Jianxing He; Stephen K Van Den Eeden; Zhi-Hua Zhu; Wen Gao; Patrick T Pham; Michael S Mulvihill; Fatemeh Ziaei; Huanrong Zhang; Bo Su; Xiuyi Zhi; Charles P Quesenberry; Laurel A Habel; Qiuhua Deng; Zongfei Wang; Jiangfen Zhou; Huiling Li; Mei-Chun Huang; Che-Chung Yeh; Mark R Segal; M Roshni Ray; Kirk D Jones; Dan J Raz; Zhidong Xu; Thierry M Jahan; David Berryman; Biao He; Michael J Mann; David M Jablons
Journal:  Lancet       Date:  2012-01-27       Impact factor: 79.321

2.  Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.

Authors:  Marie Wislez; Fabrice Barlesi; Benjamin Besse; Julien Mazières; Patrick Merle; Jacques Cadranel; Clarisse Audigier-Valette; Denis Moro-Sibilot; Laure Gautier-Felizot; François Goupil; Aldo Renault; Elisabeth Quoix; Pierre-Jean Souquet; Anne Madroszyck; Romain Corre; David Pérol; Franck Morin; Gérard Zalcman; Jean-Charles Soria
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

3.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Authors:  Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

4.  Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.

Authors:  Ignacio I Wistuba; Carmen Behrens; Francesca Lombardi; Susanne Wagner; Junya Fujimoto; M Gabriela Raso; Lorenzo Spaggiari; Domenico Galetta; Robyn Riley; Elisha Hughes; Julia Reid; Zaina Sangale; Steven G Swisher; Neda Kalhor; Cesar A Moran; Alexander Gutin; Jerry S Lanchbury; Massimo Barberis; Edward S Kim
Journal:  Clin Cancer Res       Date:  2013-09-18       Impact factor: 12.531

5.  Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

Authors:  T Moran; J Wei; M Cobo; X Qian; M Domine; Z Zou; I Bover; L Wang; M Provencio; L Yu; I Chaib; C You; B Massuti; Y Song; A Vergnenegre; H Lu; G Lopez-Vivanco; W Hu; G Robinet; J Yan; A Insa; X Xu; M Majem; X Chen; R de Las Peñas; N Karachaliou; M A Sala; Q Wu; D Isla; Y Zhou; N Baize; F Zhang; J Garde; P Germonpre; S Rauh; H ALHusaini; M Sanchez-Ronco; A Drozdowskyj; J J Sanchez; C Camps; B Liu; R Rosell; B Colinet; J De Grève; P Germonpré; H Chen; X Chen; J Du; Y Gao; J Hu; W Hu; W Kong; L Li; R Li; X Li; B Liu; J Liu; H Lu; X Qian; W Ren; Y Song; L Wang; J Wei; L Wen; Q Wu; X Xiao; X Xu; J Yan; J Yang; M Yang; Y Yang; J Yin; C You; L Yu; X Yue; F Zhang; J Zhang; Y Zhou; L Zhu; Z Zou; N Baize; P Bombaron; C Chouaid; E Dansin; P Fournel; G Fraboulet; R Gervais; S Hominal; S Kahlout; H Lecaer; H Lena; J LeTreut; C Locher; O Molinier; I Monnet; G Oliviero; G Robinet; R Schoot; P Thomas; A Vergnènegre; G Berchem; S Rauh; H Al Husaini; F Aparisi; E Arriola; I Ballesteros; I Barneto; R Bernabé; A Blasco; J Bosch-Barrera; I Bover; V Calvo de Juan; C Camps; E Carcereny; S Catot; M Cobo; R De Las Peñas; M Dómine; E Felip; M R García-Campelo; C García-Girón; R García-Gómez; R Garcia-Sevila; J Garde; A Gasco; J Gil; J L González-Larriba; S Hernando-Polo; E Jantus; A Insa; D Isla; B Jiménez; P Lianes; R López-López; A López-Martín; G López-Vivanco; J A Macias; M Majem; J L Marti-Ciriquian; B Massuti; R Montoyo; D Morales-Espinosa; T Morán; M A Moreno; C Pallares; M Parera; R Pérez-Carrión; R Porta; M Provencio; N Reguart; R Rosell; F Rosillo; M A Sala; J M Sanchez; I Sullivan; J Terrasa; J M Trigo; J Valdivia; N Viñolas; S Viteri; M Botia-Castillo; J L Mate; M Perez-Cano; J L Ramirez; B Sanchez-Rodriguez; M Taron; M Tierno-Garcia; E Mijangos; J Ocaña; E Pereira; J Shao; X Sun; R O'Brate
Journal:  Ann Oncol       Date:  2014-08-27       Impact factor: 32.976

6.  Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

Authors:  Reginald V N Lord; Jan Brabender; David Gandara; Vicente Alberola; Carlos Camps; Manuel Domine; Felip Cardenal; José M Sánchez; Paul H Gumerlock; Miquel Tarón; José J Sánchez; Kathleen D Danenberg; Peter V Danenberg; Rafael Rosell
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

7.  Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

Authors:  Gerold Bepler; Charles Williams; Michael J Schell; Wei Chen; Zhong Zheng; George Simon; Shirish Gadgeel; Xiuhua Zhao; Fred Schreiber; Julie Brahmer; Alberto Chiappori; Tawee Tanvetyanon; Mary Pinder-Schenck; Jhanelle Gray; Eric Haura; Scott Antonia; Juergen R Fischer
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

8.  Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC.

Authors:  Luis Paz-Ares; Denis Soulières; Joachim Moecks; Ilze Bara; Tony Mok; Barbara Klughammer
Journal:  J Cell Mol Med       Date:  2014-08-06       Impact factor: 5.310
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.